GeminIQ Website Logo

Viewing APGE free

Subscribe for full history, 50+ metrics, screener, watchlist...

Apogee Therapeutics, Inc.

APGE

Companies in Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc. (APGE) — SEC Financial Statements & Analysis

Apogee Therapeutics, Inc. (APGE) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash
-----------125
Cash Equivalents At Carrying Value
452132108124107142119307485118188-
Marketable Securities Current
608599419381406379407369331277235-
Prepaid Expense And Other Assets Current
1411131189864346
Assets Current
1,074741540516522530534682821398426131
Marketable Securities Noncurrent
19817362116168210228113----
Property Plant And Equipment Net
5666621110--
Operating Lease Right Of Use Asset
891011121112422--
Other Assets Noncurrent
9999701000--
Assets
1,294937626658714754776801824401426131
Liabilities And Stockhold…
Liabilities Current
Temporary Equity Carrying Amount Attributable To P…
-----------177
Common Unit Issuance Value
-----------2
Accounts Payable Current
1106212642111
Operating Lease Liability Current
3444433211--
Accrued Liabilities Current
------28171617166
Liabilities Current
332834323329332522211718
Liabilities Noncurrent
Operating Lease Liability Noncurrent
5567899211--
Liabilities
383340384137422722211718
Limited Liability Company…
Temporary Equity Shares Authorized
-----------65
Temporary Equity Shares Issued
-----------65
Temporary Equity Shares Outstanding
-----------65
Temporary Equity Liquidation Preference
-----------169
Common Stock Value
000000000---
Additional Paid In Capital
1,8921,4651,0781,0461,0341,022970964958503501-
Accumulated Other Comprehensive Income Loss Net Of…
-1111113-0-000-
Retained Earnings Accumulated Deficit
-636-562-492-427-361-306-239-190-156-124-92-71
Members Equity
1,256904586619673717734774801380409-64
Liabilities And Stockholders Equity
1,294937626658714754776801824401426131
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
400400400400400400400400400400400400
Series Preferred Units
---------0020
Common Stock Shares Issued
7569606060595958585151-
Shares Outstanding
7568595958585757562448-
Series B Preferred Units
---------03412
Common Unit Authorized
---------005
Common Unit Issued
---------055
Common Unit Outstanding
---------055
Preferred Stock Shares Authorized
---------1010-
Preferred Stock Par Or Stated Value Per Share
---------00-
Preferred Stock Shares Issued
---------00-
Preferred Stock Shares Outstanding
---------00-

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
20262.74%57.10%----------
20253.54%19.91%-4.62%9.29%15.09%63.32%35.19%33.49%15.40%9.74%20.72%14.45%
2024-20.94%-27.90%-16.42%6.28%22.54%22.56%-12.87%-16.70%-27.88%26.54%17.39%25.77%
2023----10.54%-26.96%-21.56%31.94%69.29%113.76%12.06%-20.52%-19.01%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
32.59
26.57
15.86
16.36
15.82
18.55
16.39
27.70
38.08
19.38
24.82
7.42
Quick Ratio
32.16
26.17
15.49
16.02
15.57
18.23
16.13
27.47
37.87
19.24
24.62
7.10
Working Capital
1.04B
713.45M
506.05M
484.57M
488.57M
501.15M
501.87M
657.24M
799.06M
377.85M
409.24M
113.05M
Leverage & Debt
Debt to Equity
0.03
0.04
0.07
0.06
0.06
0.05
0.06
0.03
0.03
0.06
0.04
0.16
Debt Ratio
0.03
0.04
0.06
0.06
0.06
0.05
0.05
0.03
0.03
0.05
0.04
0.13
Efficiency & Turnover
Asset Turnover TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-
-
-
Per Share Metrics
Diluted EPS TTM
-3.94
-4.22
-4.32
-4.07
-3.53
-3.30
-2.80
-2.32
-2.31
-
-
-
Free Cash Flow Per Share TTM
-3.44
-3.90
-4.12
-3.95
-3.32
-3.12
-2.37
-1.96
-2.13
-
-
-
Dividend Per Share TTM
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-
-
-
Growth Metrics
Net Income Growth (1Y)
33.70%
40.46%
59.35%
81.41%
76.94%
-
-
-
-
-
-
-
EPS Growth (1Y)
11.68%
27.74%
53.99%
75.47%
52.60%
-
-
-
-
-
-
-
Valuation Metrics
P/E TTM
-21.35
-17.91
-9.21
-10.68
-10.59
-13.73
-20.96
-16.97
-28.73
-
-
-
P/B
4.67
5.07
3.98
4.10
3.23
3.49
4.54
2.87
4.16
1.84
2.15
-
Market Cap
5.86B
4.58B
2.34B
2.54B
2.17B
2.50B
3.34B
2.22B
3.34B
698.66M
878.23M
-
Enterprise Value
5.41B
4.45B
2.23B
2.41B
2.07B
2.36B
3.22B
1.92B
2.85B
580.05M
689.96M
-
Calculated Values
Free Cash Flow TTM
-239.69M
-236.91M
-241.88M
-230.90M
-193.14M
-172.33M
-134.37M
-110.97M
-106.75M
-
-
-
Net Debt
-451.80M
-131.55M
-107.91M
-124.49M
-106.92M
-142.08M
-119.07M
-307.59M
-485.75M
-118.61M
-188.27M
-125.07M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-06-22Sale
Owner: Dambkowski, Carl
Title: Chief Medical Officer
Shares: 26,400
Price/Share: $132.60
Value: $3,500,640.00
Shares Owned: 179,248
Relationship: Officer
Ownership: Direct
2026-06-22Sale
Owner: Henderson, Michael Thomas
Title: Chief Executive Officer
Shares: 80,000
Price/Share: $132.54
Value: $10,603,200.00
Shares Owned: 1,015,987
Relationship: Director,Officer
Ownership: Direct
2026-06-10Sale
Owner: Henderson, Michael Thomas
Title: Chief Executive Officer
Shares: 20,000
Price/Share: $84.59
Value: $1,691,800.00
Shares Owned: 1,095,987
Relationship: Director,Officer
Ownership: Direct
2026-06-03Sale
Owner: Dambkowski, Carl
Title: Chief Medical Officer
Shares: 5,500
Price/Share: $78.71
Value: $432,905.00
Shares Owned: 205,648
Relationship: Officer
Ownership: Direct
2026-05-13Sale
Owner: Henderson, Michael Thomas
Title: Chief Executive Officer
Shares: 20,000
Price/Share: $82.32
Value: $1,646,400.00
Shares Owned: 1,115,987
Relationship: Director,Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
95.35%
Inst. Shares: 66,431,969
Shares Outstanding: 69,668,439
2025-12-31
107.18%
Inst. Shares: 65,047,271
Shares Outstanding: 60,690,820
2025-09-30
99.80%
Inst. Shares: 58,657,109
Shares Outstanding: 58,773,731
2025-06-30
96.55%
Inst. Shares: 56,410,810
Shares Outstanding: 58,428,344
2025-03-31
103.30%
Inst. Shares: 60,113,815
Shares Outstanding: 58,195,272

Research Faster.
Invest Smarter.

Apogee Therapeutics, Inc. (APGE) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.